ReviewDrugs2006
Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- H1-antihistamines for chronic spontaneous urticaria.The Cochrane database of systematic reviews · 2014Pooled it
- Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers.Clinical pharmacology in drug development · 2020Trial
- Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine.British journal of clinical pharmacology · 2008Trial
- Antipruritic Placebo Effects by Conditioning H1-antihistamine.Psychosomatic medicineTrial
- Synergic Efficacy of a Multicomponent Nutraceutical Add-On Therapy in Seasonal Allergic Rhinitis in Children: A Prospective, Randomized, Parallel-Group Study.Journal of clinical medicine · 2025Article
- Unravelling allergic rhinitis: exploring pathophysiology, advances in treatment, and future directions.Frontiers in allergy · 2025Review
- Article
- Nano-Spray-Dried Levocetirizine Dihydrochloride with Mucoadhesive Carriers and Cyclodextrins for Nasal Administration.Pharmaceutics · 2023Article
- Topical Formulation of Nano Spray-Dried Levocetirizine Dihydrochloride against Allergic Edema.Pharmaceutics · 2022Article
- Parkinsonism Attenuation by Antihistamines via Downregulating the Oxidative Stress, Histamine, and Inflammation.ACS omega · 2022Article
- Levocetirizine and montelukast in the COVID-19 treatment paradigm.International immunopharmacology · 2022Article
- Prescribed drugs containing nitrogen heterocycles: an overview.RSC advances · 2020Review
- A case of levocetirizine-induced liver injury.Clinical and molecular hepatology · 2016Article
- Comparison of levocetirizine pharmacokinetics after single doses of levocetirizine oral solution and cetirizine dry syrup in healthy Japanese male subjects.Journal of drug assessment · 2014Article
- Levocetirizine inhibits migration of immune cells to lymph nodes and induces treg cells in a murine type I allergic conjunctivitis model.The open ophthalmology journal · 2012Article
- Levocetirizinium dipicrate.Acta crystallographica. Section E, Structure reports online · 2010Article
- Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety.Indian journal of pharmacology · 2010Article
- The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect?Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2009Article
- Oral bioavailability and pharmacokinetic study of cetrizine HCl in Iranian healthy volunteers.Research in pharmaceutical sciences · 2009Article
- H1 antihistamines: current status and future directions.The World Allergy Organization journal · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetirizine is effective and generally well tolerated in the treatment of allergic rhinitis and CIU. Its pharmacological profile offers many positive aspects: a rapid onset and long duration of antihistaminic effect; rapid absorption and high bioavailability; a low potential for drug interactions; a low volume of distribution; and a lack of effect on cognition, psychomotor function and the cardiovascular system. Allergen challenge chamber studies suggest that levocetirizine has better efficacy than desloratadine, loratadine or fexofenadine. Well controlled, long-term studies with other later-generation H(1) receptor antagonists are required to fully define its clinical profile relative to other agents in this class. Overall, levocetirizine is a valuable addition to the oral H(1) receptor antagonists available for the treatment of allergic rhinitis and as first-line therapy in patients with CIU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.